Innate Pharma (IPHA) Net Income towards Common Stockholders (2019 - 2025)

Innate Pharma (IPHA) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$24.3 million the latest figure, recorded in Q2 2025.

• Quarterly Net Income towards Common Stockholders rose 13.81% year-over-year to -$24.3 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$108.8 million (down 13.6% YoY) and the FY2025 annual result came in at -$24.7 million, down 345.69% from the prior year.
• Net Income towards Common Stockholders improved to -$24.3 million in Q2 2025 per IPHA's latest filing, from -$56.3 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for IPHA reached as high as $122.3 million in Q4 2021 and fell as low as -$56.3 million in Q4 2024.
• A 5-year average of $4.1 million and a median of -$8.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders jumped 270.12% — and 2023, when it slumped 3091.78%.
• Year by year, Net Income towards Common Stockholders stood at $122.3 million in 2021, then plunged by 49.6% to $61.6 million in 2022, then plunged by 113.98% to -$8.6 million in 2023, then slumped by 553.51% to -$56.3 million in 2024, then soared by 56.86% to -$24.3 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$24.3 million, -$56.3 million, and -$28.2 million for Q2 2025, Q4 2024, and Q2 2024 respectively.